HighField Biopharmaceuticals, a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced the U.S. Food and Drug Administration has granted clearance of the company’s Investigational New Drug application for HF158K1, a drug encapsulated immunoliposome containing doxorubicin.
